Keyword: Gilead Sciences

Terns names ex-Gilead executive as CMO; Spectrum sells all FDA-approved drugs to Aurobindo; Aslan's varlitinib fails in gastric cancer.

Pfizer closes two Hospira plants in India; Gilead licenses Yuhan's NASH programs; Fujifilm is expanding its footprint in the U.S.

Monday was a good-news-bad-news day for Gilead as the Supreme Court handed down two decisions about which appeals they'll consider.

The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.

With Bristol kicking off 2019 at the dealmaking table, will other companies follow suit? Drugmakers such as AbbVie, Gilead have the need—and the funds.

Allegations in nearly a dozen kickbacks lawsuits against top pharma companies are unfounded, the government said.

With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that.

Joining the list of top 10 pharma TV spenders were a group of new brands including Aimovig, Mavyret and Truvada.

​​​​​​​AbbVie is pushing its time-to-cure advantage in new ads for hepatitis C treatment Mavyret that emphasize a cure “in only 8 weeks.”

The most expensive drugs in the U.S. feature commercial hits as well as lesser-known ones, with several Big Pharma products in the mix.